Article

Opthalmology Times October 1,2009

Fully searchable access to the October 1, 2009 issue

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
Related Content
Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa
March 26th 2025

Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced
March 26th 2025

Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint
March 24th 2025

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

© 2025 MJH Life Sciences

All rights reserved.